GlassScriptPhysician profile
Shawna M Jones
NPI 1447451786
$265,947.78
in general payments reported to CMS, 2019-2025
22 companies · $36K in 2025
The $36K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20K · 2022: $62K · 2023: $72K · 2024: $76K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $139K · Consulting Fee: $19K · Travel and Lodging: $16K · Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $138,675.00 |
| Consulting Fee | $18,910.75 |
| Travel and Lodging | $16,460.70 |
| Food and Beverage | $10,075.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $183,188.20 | 2021-2025 | |
| Allergan, INC. | $78,567.36 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $1,190.06 | 2021-2025 | |
| Lilly USA, LLC | $608.52 | 2021-2023 | Taltz, Olumiant |
| Genzyme Corporation | $334.21 | 2021-2023 | |
| Revance Therapeutics, INC. | $300.70 | 2024-2025 | Daxxify |
| Galderma Laboratories, L.P. | $281.56 | 2024-2025 | |
| Incyte Corporation | $272.58 | 2021-2023 | Opzelura |
| Pfizer INC. | $260.86 | 2021-2023 | |
| Janssen Biotech, INC. | $189.69 | 2021-2023 | Tremfya |
| Sun Pharmaceutical Industries INC. | $133.18 | 2021-2022 | |
| Chiesi USA, INC. | $123.25 | 2021 | |
| Ucb, INC. | $90.45 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $74.00 | 2022-2023 | Dupixent |
| Leo Pharma INC. | $69.49 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $60.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $54.10 | 2022-2023 | Sotyktu |
| Amgen INC. | $41.77 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $36.35 | 2022-2023 | Valchlor |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $28.81 | 2021 | |
| Dermavant Sciences, INC. | $27.31 | 2023-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $15.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawna Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.